Get the Stockscreener App
17.88
1.53%
+0.27
Kiniksa Pharmaceuticals Ltd stock is currently priced at $17.88, with a 24-hour trading volume of 292.44K.
It has seen a +1.53% increased in the last 24 hours and a -10.47% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $17.74 pivot point. If it approaches the $17.98 resistance level, significant changes may occur.
Previous Close:
$17.61
Open:
$17.84
24h Volume:
292.44K
Market Cap:
$1.27B
Revenue:
$301.77M
Net Income/Loss:
$8.65M
P/E Ratio:
-162.55
EPS:
-0.11
Net Cash Flow:
$13.17M
1W Performance:
+5.74%
1M Performance:
-10.47%
6M Performance:
+18.02%
1Y Performance:
+60.36%
1D Range:
$17.45
$18.05
52W Range:
$10.64
$22.09
Kiniksa Pharmaceuticals Ltd Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals Ltd
Sector
Industry
Phone
441-295-5950
Address
Clarendon House, 2 Church Street, Hamilton
Kiniksa Pharmaceuticals Ltd Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
Kiniksa Pharmaceuticals Ltd Stock (KNSA) Latest News
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire Inc.
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
GlobeNewswire Inc.
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
GlobeNewswire Inc.
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Zacks Investment Research
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
Zacks Investment Research
Kiniksa Pharmaceuticals Ltd Stock (KNSA) Financials Data
Kiniksa Pharmaceuticals Ltd (KNSA) Revenue 2024
KNSA reported a revenue (TTM) of $301.77 million for the quarter ending March 31, 2024, a +27.69% rise year-over-year.
Kiniksa Pharmaceuticals Ltd (KNSA) Net Income 2024
KNSA net income (TTM) was $8.65 million for the quarter ending March 31, 2024, a -95.59% decrease year-over-year.
Kiniksa Pharmaceuticals Ltd (KNSA) Cash Flow 2024
KNSA recorded a free cash flow (TTM) of $13.17 million for the quarter ending December 31, 2023, a +130.99% increase year-over-year.
Kiniksa Pharmaceuticals Ltd (KNSA) Earnings per Share 2024
KNSA earnings per share (TTM) was $0.11 for the quarter ending March 31, 2024, a -96.03% decline year-over-year.
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
1.53%
3.38%
Cap:
|
Volume (24h):